Back to results
US 2010/0143946 A1Published application
Alpha-synuclein kinase
AssigneeElan Pharma International Limited
InventorsJOHN P. ANDERSON, KELLY BANDUCCI, GURIQBAL S. BASI, DAVID CHEREAU, TAMIE J. CHILCOTE, NORMAND L. FRIGON, JR., JASON GOLDSTEIN, IRENE GRISWOLD-PRENNER
Life of this patent
Estimating the term…
Abstract
The invention provides agents and methods for treatment of diseases associated with Lewy body diseases (LBDs) in the brain of a patient. Preferred agents include inhibitors of PLK2 kinase.
Claims6
-21. (canceled)
A method of identifying an agent reduces alpha-synuclein phosphorylation in a mammalian cell expressing alpha-synuclein comprising selecting an agent that
- a) reduces activity of PLK2 in a cell expressing PLK2;
- and
- b) does not reduce activity of PLK1 in a cell expressing PLK1, or reduces activity of PLK1 at a higher EC50 than for PLK2;
- and/or
- c) does not reduce activity of PLK3 in a cell expressing PLK3, or reduces activity of PLK3 at a higher EC50 than for PLK2;
- and/or
- d) does not reduce activity of PLK4 in a cell expressing PLK4, or reduces activity of PLK4 at a higher EC50 than for PLK2.
4 more elements
25-30. (canceled)
Dependencies are inferred from the claim text.